Castle Biosciences, Inc. (CSTL) Stock Forecast
CSTL analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 9 analysts
- Price target
- $45.22 average of analyst targets
- Upside to target
- +41.5% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.38
- 52-week range
- $18.15 – $43.04
CSTL analyst ratings
9 analystsNumber of analysts at each rating.
CSTL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CSTL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.42 | −$0.25 | −$0.02 | −1,650.0% | 9 |
| Current fiscal year (2026) | −$1.26 | −$1.38 | −$1.06 | −$0.83 | −51.5% | 9 |
| Next fiscal year (2027) | −$0.91 | −$1.56 | −$0.43 | −$1.26 | +27.4% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CSTL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $92.5M | $91.2M | $93.5M | +11.4% | 8 |
| Current fiscal year (2026) | $373.5M | $371.4M | $374.4M | +8.5% | 9 |
| Next fiscal year (2027) | $412.5M | $399.2M | $425.6M | +10.4% | 9 |
CSTL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CSTL revenue: reported and forecast
CSTL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.30 | −$0.36 | −$0.36 | −$0.35 | −$0.35 | +16.2% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.42 | −$1.27 | −$1.27 | −$1.27 | −$1.26 | −11.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.96 | −$0.99 | −$0.99 | −$0.94 | −$0.91 | −4.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CSTL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CSTL beat in 11 of 12.
What analysts expect from CSTL
9 analysts cover Castle Biosciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $45.22, 41.5% above the latest close of $31.96. Analysts expect earnings of −$1.26 per share for 2026, −51.5% from a year earlier. For 2027 the average estimate is −$0.91 per share on revenue of $412.5 million. Castle Biosciences beat the EPS estimate in 11 of the last 12 quarters.
Related: CSTL income statement, CSTL key metrics, CSTL chart. See the CSTL stock overview for the latest quote and news.
CSTL forecast FAQ
What is Castle Biosciences's price target?
The average analyst price target for Castle Biosciences is $45.22, 41.5% above the latest close of $31.96.
Is Castle Biosciences a buy, hold or sell?
Of 9 analysts covering Castle Biosciences, 9 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Castle Biosciences's EPS forecast?
Analysts forecast −$1.26 per share for 2026 (range −$1.38 to −$1.06); for 2027 the estimate is −$0.91.
What is Castle Biosciences's revenue forecast?
The average revenue estimate for 2026 is $373.5 million, growth of 8.5%; for 2027 it is $412.5 million.
When does Castle Biosciences report earnings?
Castle Biosciences is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.38.
Does Castle Biosciences usually beat earnings estimates?
Castle Biosciences reported EPS at or above the analyst estimate in 11 of the last 12 quarters.